Indiana Historical Society

Lilly Confirms Date and Conference Call for First-Quarter 2021 Financial Results Announcement

Retrieved on: 
Tuesday, April 6, 2021
INDIANA, States of the United States, Midwestern United States, Eli Lilly, Indiana Historical Society, LLY, New York Stock Exchange, Conference call, Indianapolis, Lilly

INDIANAPOLIS, April 6, 2021 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2021 financial results on Tuesday, April 27, 2021.

Key Points: 
  • INDIANAPOLIS, April 6, 2021 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2021 financial results on Tuesday, April 27, 2021.
  • Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.
  • The conference call will begin at 9 a.m. Eastern time.
  • Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations .

Follica Adds Two Leaders in Aesthetic Medicine and Dermatology to Its Board of Directors

Retrieved on: 
Thursday, January 14, 2021
Medical devices, Health, Technology, Software, Pharmaceutical, Biotechnology, Eli Lilly, Indiana Historical Society, INDIANA, States of the United States

View the full release here: https://www.businesswire.com/news/home/20210114005208/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210114005208/en/
    Follica announced the appointment of two veteran biotech executives to its Board of Directors.
  • Mr. Wiggans guided Dermira through Eli Lillys acquisition of the company for approximately $1.1 billion in January of 2020.
  • We are very pleased to welcome Tom and Michael to the Follica board, said Jason Bhardwaj, Chief Executive Officer of Follica.
  • They bring valuable insights in both product and business development, with particular expertise in dermatology and aesthetic medicine.

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against NextCure, Inc. (NXTC)

Retrieved on: 
Tuesday, September 22, 2020
Eli Lilly, Indiana Historical Society, Class action, GME, Lilly, INDIANA, States of the United States

NextCure had been developing NC318 using proceeds from a 2018 research and development collaboration agreement with Eli Lilly.

Key Points: 
  • NextCure had been developing NC318 using proceeds from a 2018 research and development collaboration agreement with Eli Lilly.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq.
  • of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected] .

Lilly Announces Leadership Changes

Retrieved on: 
Wednesday, September 9, 2020
INDIANA, States of the United States, Eli Lilly, Indiana Historical Society, Articles, Lilly, LLY

INDIANAPOLIS, Sept. 9, 2020 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) announced today that Patrik Jonsson, senior vice president and president of Lilly Bio-Medicines, is being named to the new role of senior vice president, president of Lilly USA, and Chief Customer Officer.

Key Points: 
  • INDIANAPOLIS, Sept. 9, 2020 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) announced today that Patrik Jonsson, senior vice president and president of Lilly Bio-Medicines, is being named to the new role of senior vice president, president of Lilly USA, and Chief Customer Officer.
  • "Ilya's effective leadership of our largest U.S. franchise, U.S. Diabetes, and his broad experience across many parts of our business have prepared him well to lead Lilly Bio-Medicines."
  • This press release contains forward-looking statements about leadership changes and reflects Lilly's current beliefs.
  • There are risks and uncertainties related to leadership changes.

Eli Lilly and Company Foundation Pledges $25 Million to Combat Racial Injustice

Retrieved on: 
Saturday, June 13, 2020
INDIANA, Philanthropists, States of the United States, Eli Lilly, Indiana Historical Society, Lilly Endowment, Lilly, LLY

INDIANAPOLIS, June 13, 2020 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) and the Lilly Foundation announced today a pledge of $25 million and 25,000 volunteer hours over five years to decrease the burden of racial injustice and its effects on local and national communities of color.

Key Points: 
  • INDIANAPOLIS, June 13, 2020 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) and the Lilly Foundation announced today a pledge of $25 million and 25,000 volunteer hours over five years to decrease the burden of racial injustice and its effects on local and national communities of color.
  • "Lilly and the Lilly Foundation have a long history of standing beside our neighbors and communities," said Tiffany Benjamin, president of the Lilly Foundation.
  • The Lilly Foundation's financial commitment over five years will help develop and support effective solutions to racial inequity and social injustice primarily in Indianapolis, its surrounding counties and nationally.
  • "This is personal for me and for the whole company," said David Ricks, Lilly chairman and CEO.

Evox Therapeutics Announces a Multi-target RNAi and Antisense Research Collaboration and License Agreement With Lilly

Retrieved on: 
Tuesday, June 9, 2020
RNA, Nucleic acids, Branches of biology, Life sciences, Biology, Eli Lilly, Indiana Historical Society, Exosome complex, RNA interference, Oligonucleotide

OXFORD, England, June 9, 2020 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, is pleased to announce a research collaboration and license agreement with Eli Lilly and Company to leverage Evox's proprietary DeliverEXplatform to develop and deliver RNA interference (RNAi) & antisense oligonucleotide (ASO) drug payloads for the potential treatment of neurological disorders.

Key Points: 
  • OXFORD, England, June 9, 2020 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, is pleased to announce a research collaboration and license agreement with Eli Lilly and Company to leverage Evox's proprietary DeliverEXplatform to develop and deliver RNA interference (RNAi) & antisense oligonucleotide (ASO) drug payloads for the potential treatment of neurological disorders.
  • During this research collaboration and five-target license agreement, Evox will be responsible for exosome engineering in order to achieve brain/CNS-targeting, drug loading and analytics and some in vitro assay development, as well as material supply for initial in vivo studies.
  • Any resulting candidate handover and technology transfer to Lilly will occur after pre-clinical proof of concept studies have been completed.
  • Under the terms of the agreement, Evox will receive a $20 million cash up-front payment, research funding over three years, as well as a $10 million investment from Lilly in exchange for a convertible bond from the Company.

Vaxcyte Appoints Halley E. Gilbert to Board of Directors

Retrieved on: 
Wednesday, June 3, 2020
Eli Lilly, Indiana Historical Society, Economy of the United States, Articles, Life sciences

Were excited to welcome Halley to Vaxcytes board of directors, said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte.

Key Points: 
  • Were excited to welcome Halley to Vaxcytes board of directors, said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte.
  • In this capacity, Ms. Gilbert oversaw corporate and business development, legal, compliance and government affairs.
  • Ms. Gilbert currently also serves on the boards of directors of Arcutis Biotherapeutics, a medical dermatology company, and CytomX Therapeutics, a life sciences company.
  • She previously served on the board of directors of Dermira, Inc., a medical dermatology company (acquired by Eli Lilly and Company), and Achaogen, Inc., a biopharmaceutical company.

Lilly Confirms Date and Conference Call for First-Quarter 2020 Financial Results Announcement

Retrieved on: 
Wednesday, April 8, 2020
INDIANA, Philanthropists, Economy of the United States, Eli Lilly, Indiana Historical Society, LLY, Lilly, Indianapolis, New York Stock Exchange

INDIANAPOLIS, April 8, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2020 financial results on Thursday, April 23, 2020.

Key Points: 
  • INDIANAPOLIS, April 8, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2020 financial results on Thursday, April 23, 2020.
  • Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.
  • The conference call will begin at 9 a.m. Eastern time.
  • Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world.

Lilly to Provide Drive-Through COVID-19 Testing for Indianapolis Health Care Workers

Retrieved on: 
Sunday, March 22, 2020
INDIANA, Philanthropists, Health, Eli Lilly, Indiana Historical Society, Indianapolis, LLY, Severe acute respiratory syndrome

INDIANAPOLIS, March 22, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will offer drive-through testing for SARS-CoV-2, the virus that causes COVID-19, to Indianapolis area health care workers beginning Monday, March 23, as a service to the community and in an effort to protect health care providers working on the front lines during this epidemic.

Key Points: 
  • INDIANAPOLIS, March 22, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will offer drive-through testing for SARS-CoV-2, the virus that causes COVID-19, to Indianapolis area health care workers beginning Monday, March 23, as a service to the community and in an effort to protect health care providers working on the front lines during this epidemic.
  • Now Lilly is expanding the service to the community by offering drive through-testing at Lilly's Indianapolis headquarters.
  • At this time, only active health care workers are eligible, and they must have a physician's order requesting testing for COVID-19.
  • Many health care workers are currently unable to receive testing through existing diagnostic facilities, and Lilly is initially focused on addressing this unmet need.

Enrique Conterno, Senior Vice President and President of Lilly Diabetes and Lilly USA, to Retire at End of Year; Mike Mason to Succeed Conterno

Retrieved on: 
Wednesday, October 23, 2019
Eli Lilly, Indiana Historical Society, Articles, Health, Lilly, LLY, Industries

INDIANAPOLIS, Oct. 23, 2019 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) announced today that Enrique Conterno, senior vice president of Lilly and president of Lilly Diabetes and Lilly USA, will retire at the end of the year after 27 years of service with the company.

Key Points: 
  • INDIANAPOLIS, Oct. 23, 2019 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) announced today that Enrique Conterno, senior vice president of Lilly and president of Lilly Diabetes and Lilly USA, will retire at the end of the year after 27 years of service with the company.
  • Mike Mason,who currently serves as senior vice president, connected care & insulins, will succeed Conterno.
  • Mason's new title will be senior vice president of Lilly and president of Lilly Diabetes.
  • "Mike is a 30-year Lilly veteran with deep experience across the company, including significant expertise in our diabetes business.